Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Comment by FarmerBettyon Dec 14, 2022 9:51am
215 Views
Post# 35170609

RE:RE:Recent insider buying

RE:RE:Recent insider buying Very slim buying, even compared to mid year insider buying on the Nasdaq listing. For the most part just the two directors over the year Williams and Kirwin, the other directors non-existent. 
Getting close to a 5 year low, with really no news since the spring with the exception of minimum regulatory requirements. Could it be that the sophisticated buyers and sellers on the Nasdaq that bball or Gbathat made reference to earlier in the year about the benifits of going to the Nasdaq are engineering the price down? A large increase in volume over the last couple of weeks! Remember this management group said in August amongst many misleading statements "We expect our cash is sufficient to finance the company's operations for the next twelve months", then issued a PP two months later to the Boston Group. Is there a massive PP coming to the Boston group? 
<< Previous
Bullboard Posts
Next >>